Sulfonylureas: do we need to introspect safety again?

Bibliography

• Kar P, Holt RI. The effect of sulphonylureas on the microvascular and macrovascular complications of diabetes. Cardiovasc Drugs Ther 2008;22(3):207-13
   PubMed Web of Science ®Google Scholar
• Bell DS. Do sulfonylurea drugs increase the risk of cardiac events? CMAJ 2006;174(2):185-6
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2008.
   Google Scholar
• Nathan DM, Buse JB, Davidson MB, Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009;52:17-30
   PubMed Web of Science ®Google Scholar
• Valensi P, Slama G. Sulphonylureas and cardiovascular risks: facts and controversies. Br J Diabetes Vasc Dis 2006;6(4):159-65
   Google Scholar
• Schwartz TB, Meinert CL. The UGDP controversy: thirty-four years of contentious ambiguity laid to rest. Perspect Biol Med 2004;47(4):564-74
   PubMed Web of Science ®Google Scholar
• Rao AD, Kuhadiya N, Reynolds K, Is the combination of sulphonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies. Diabetes Care 2008;31(8):1672-8
   PubMed Web of Science ®Google Scholar
• Lefer DJ, Nichols CG, Coetzee WA. Sulfonylurea receptor 1 subunits of ATP-sensitive potassium channels and myocardial ischemia/reperfusion injury. Trends Cardiovasc Med 2009;19(2):61-7
   PubMed Web of Science ®Google Scholar
• Miki T, Liss B, Minami K, ATP-sensitive K+ channels in the hypothalamus are essential for the maintenance of glucose homeostasis. Nat Neurosci 2001;4(5):507-12
   PubMed Web of Science ®Google Scholar
• Nagashima K, Takahashi A, Ikeda H, Sulfonylurea and non-sulfonylurea hypoglycemic agents: pharmacological properties and tissue selectivity. Diabetes Res Clin Pract 2004;66(S1):75-8
   Google Scholar
• Khalangot M, Tronmcho M, Kravchenko V, Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study. Diabetes Res Clin Pract 2009;86(3):247-53
   PubMed Web of Science ®Google Scholar
• Turner R, Cull C, Holman R. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 1996;124(1 Pt 2):136-45
   PubMed Web of Science ®Google Scholar
• Zeller M, Danchin N, Simon D, for the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction investigators. Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction. J Clin Endocrinol Metab 2010;95(11):4993-5002
   PubMed Web of Science ®Google Scholar
• Kilo C, Miller JP, Williamson JR. The crux of the UGDP. Spurious results and biologically inappropriate data analysis. Diabetologia 1980;18(3):179-85
   PubMed Web of Science ®Google Scholar
• Sato T, Nishida H, Miyazaki M, Effects of sulfonylureas on mitochondrial ATP-sensitive K+ channels in cardiac myocytes: implications for sulfonylurea controversy. Diabetes Metab Res Rev 2006;22(5):341-7
   PubMed Web of Science ®Google Scholar
• Kilo C, Miller JP, Williamson JR. The Achilles heel of the University Group Diabetes Program. JAMA 1980;243(5):450-7
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, 10-year follow up of glucose control in type 2 diabetes. N Engl J Med 2008;359(15):1577-89
   PubMed Web of Science ®Google Scholar
• Brady PA, Terzic A. The sulfonylurea controversy: more questions from the heart. J Am Coll Cardiol 1998;31(5):950-6
   PubMed Web of Science ®Google Scholar
• Zarich SW. Potential of glucose-lowering drugs to reduce cardiovascular events. Curr Diab Rep 2009;9(1):87-94
   PubMed Web of Science ®Google Scholar
• Thisted H, Johnsen PS, Rungby J. Sulfonylureas and the risk of myocardial infarction. Metabolism 2006;55(Suppl 1):16S-9S
   Google Scholar
• Jennings PE. Vascular benefits of gliclazide beyond glycemic control. Metabolism 2000;49(10 Suppl 2):17-20
   PubMed Web of Science ®Google Scholar
• Cacciapuoti F, Spiezia R, Bianchi U, Effectiveness of glibenclamide on myocardial ischemic ventricular arrhythmias in non-insulin-dependent diabetes mellitus. Am J Cardiol 1991;67(9):843-7
   PubMed Web of Science ®Google Scholar
• Monami M, Balzi D, Lamanna C, Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. Diabetes Metab Res Rev 2007;23:479-84
   PubMed Web of Science ®Google Scholar
• Huffmyer J, Raphael J. Physiology and pharmacology of myocardial preconditioning and postconditioning. Semin Cardiothorac Vasc Anesth 2009;13(1):5-18
   PubMedGoogle Scholar
• Engler RL, Yellon DM. Sulfonylurea KATP blockade in type II diabetes and preconditioning in cardiovascular disease. Time for reconsideration. Circulation 1996;94(9):2297-301
   PubMed Web of Science ®Google Scholar
• Meier JJ, Gallwitz B, Schmidt WE, Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important? Heart 2004;90(1):9-12
   PubMed Web of Science ®Google Scholar
• Huizar JF, Gonzalez LA, Alderman J, Sulfonylureas attenuate electrocardiographic ST-segment elevation during an acute myocardial infarction in diabetics. J Am Coll Cardiol 2003;42(6):1017-21
   PubMed Web of Science ®Google Scholar
• Simpson SH, Majumdar SR, Tsuyuki RT, Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ 2006;174(2):169-74
   PubMed Web of Science ®Google Scholar
• Garratt KN, Brady PA, Hassinger NL, Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999;33(1):119-24
   PubMed Web of Science ®Google Scholar
• Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 1997;314(7093):1512-15
   PubMed Web of Science ®Google Scholar
• Malmberg K, Ryden L, Wedel H, Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005;26(7):650-61
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Miller ME, Byington RP, Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358(24):2545-59
   PubMed Web of Science ®Google Scholar
• Macisaac RJ, Jerums G. Intensive glucose control and cardiovascular outcomes in type 2 diabetes (April 2010). Heart Lung Circ 2010; published online Aug 29, 2010, doi:10.1016/j.hlc.2010.07.013
   Web of Science ®Google Scholar
• Ferrannini E, Natali A. Essential hypertension, metabolic disorders, and insulin resistance. Am Heart J 1991;121(4 Pt 2):1274-82
   PubMed Web of Science ®Google Scholar
• Quayle MJ, Nelson T, Standen BN. ATP-Sensitive and inwardly rectifying potassium channels in smooth muscle. Physiol Rev 1997;77:1166-232
   Web of Science ®Google Scholar
• Sato N, Nakayama T, Asai S, A haplotype in the human Sur2 gene is associated with essential hypertension. J Hum Hypertens 2006;20(1):87-90
   PubMed Web of Science ®Google Scholar
• Seino S, Miki T. Physiological and pathophysiological roles of ATP-sensitive K+ channels. Prog Biophys Mol Biol 2003;81(2):133-76
   PubMed Web of Science ®Google Scholar
• Shi NQ, Ye B, Makielski JC. Function and distribution of the SUR isoforms and splice variants. J Mol Cell Cardiol 2005;39(1):51-60
   PubMed Web of Science ®Google Scholar
• Yosefy C, Magen E, Kiselevich A, Rosiglitazone improves, while Glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity. J Cardiovasc Pharmacol 2004;44(2):215-22
   PubMed Web of Science ®Google Scholar
• Hasslacher C, Ritz E, Tschope W, Hypertension in Diabetes. Kidney Int Suppl 1988;25:133S-7S
   Google Scholar
• Pollare T, Lithell H, Berne C. Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism 1990;39(2):167-74
   PubMed Web of Science ®Google Scholar
• Boyko EJ, Leonetti DL, Bergstrom RW, Visceral adiposity, fasting plasma insulin, and blood pressure in Japanese-Americans. Diabetes Care 1995;18(2):174-81
   PubMed Web of Science ®Google Scholar
• Asch S, Wingard DL, Barrett-Connor EL. Are insulin and hypertension independently related? Ann Epidemiol 1991;1:231-44
   PubMedGoogle Scholar
• Muller DC, Elahi D, Pratley RE, An epidemiological test of the hyperinsulinemia-hypertension hypothesis. J Clin Endocrinol Metab 1993;76(3):544-8
   PubMed Web of Science ®Google Scholar
• Collins VR, Dowse GK, Finch CF, An inconsistent relationship between insulin and blood pressure in three Pacific island populations. J Clin Epidemiol 1990;43(12):1369-78
   PubMed Web of Science ®Google Scholar
• Saad MF, Lillioja S, Nyomba BL, Racial differences in the relation between blood pressure and insulin resistance. N Engl J Med 1991;324(11):733-9
   PubMed Web of Science ®Google Scholar
• Zimmet PZ, Collins VR, Dowse GK, Is hyperinsulinaemia a central characteristic of a chronic cardiovascular risk factor clustering syndrome? Mixed findings in Asian Indian, Creole and Chinese Mauritians. Mauritius Noncommunicable Disease Study Group. Diabet Med 1994;11(4):388-96
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352(9131):854-65
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 Diabetes (UKPDS 33). Lancet 1998;352(9131):837-53
   PubMed Web of Science ®Google Scholar
• St John Sutton M, Rendell M, Dandona P, A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 2002;25(11):2058-64
   PubMed Web of Science ®Google Scholar
• Belcher G, Lambert C, Goh KL, Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide. Int J Clin Pract 2004;58(9):833-7
   PubMed Web of Science ®Google Scholar
• Giovannucci E, Harlan DM, Archer MC, Diabetes and cancer: a consensus report. Diabetes Care 2010;33(7):1674-85
   PubMed Web of Science ®Google Scholar
• Evans JM, Donnelly LA, Emslie-Smith AM, Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330(7503):1304-5
   PubMed Web of Science ®Google Scholar
• Monami M, Lamanna C, Pala L, Treatment with insulin secretagogues and cancer-related mortality in type 2 diabetic patients a retrospective cohort study. Exp Clin Endocrinol Diabetes 2008;116(3):184-9
   PubMed Web of Science ®Google Scholar
• Sliwinska A, Sliwinski T, Kasznicki J, Effect of gliclazide on nucleotide excision repair (NER) and non-homologous DNA end joining (NHEJ) in normal and cancer cells. J Physiol Pharmacol 2010;61(3):347-53
   PubMed Web of Science ®Google Scholar
• Bowker SL, Majumdar SR, Veugelers P, Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006;29(2):254-8
   PubMed Web of Science ®Google Scholar
• Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009;52(9):1766-77
   PubMed Web of Science ®Google Scholar
• Monami M, Lamanna C, Balzi D, Sulphonylureas and cancer: a case-control study. Acta Diabetol 2009;46(4):279-84
   PubMed Web of Science ®Google Scholar
• Jonasson JM, Ljung R, Talback M, Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 2009;52(9):1745-54
   PubMed Web of Science ®Google Scholar
• Currie CJ. The longest ever randomised controlled trial of insulin glargine: study design and HbA(1c) findings. Diabetologia 2009;52(10):2234-5
   PubMed Web of Science ®Google Scholar
• Manderbacka K, Sund R, Koski S, Diabetes and depression? Secular trends in the use of antidepressants among persons with diabetes in Finland in 1997-2007. Pharmacoepidemiol Drug Saf 2011;20(4):338-43
   PubMed Web of Science ®Google Scholar
• Pawaskar MD, Anderson RT, Balkrishnan R. Self-reported predictors of depressive symptomatology in an elderly population with type 2 diabetes mellitus: a prospective cohort study. Health Qual Life Outcomes 2007;5:50
   PubMed Web of Science ®Google Scholar
• Fallon JH, Loughlin SE. Substantia Nigra. In: Paxinos G, editor, The rat nervous system. Volume 1 Academic Press; San Diego: 1985. p 353-74
   Google Scholar
• Koua J, Klorig CD, Bloomquist RJ. Potentiating effect of the ATP-sensitive potassium channel blocker glibenclamide on complex I inhibitor neurotoxicity in vitro and in vivo. Neurotoxicology 2006;27(5):826-34
   PubMed Web of Science ®Google Scholar
• Abraira C, Henderson WG, Colwell JA, Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM). Diabetes Care 1998;21(4):574-9
   PubMed Web of Science ®Google Scholar
• Bernardi H, De Weille JR, Epelbaum J, ATP-modulated K+ channels sensitive to antidiabetic Sulfonylureas are present in adenohypophysis and are involved in growth hormone release. Proc Natl Acad Sci USA 1993;90(4):1340-4
   PubMed Web of Science ®Google Scholar
• De Weille JR, Fosset M, Epelbaum J, Effectors of ATP-sensitive K+ channels inhibit the regulatory Effects of somatostatin and GH-releasing factor on growth hormone secretion. Biochem Biophys Res Commun 1992;187(2):1007-14
   PubMed Web of Science ®Google Scholar
• ter Braak EW, Appelman AM, van der Tweel I, The sulfonylurea glyburide induces impairment of glucagon and growth hormone responses during mild insulin-induced hypoglycaemia. Diabetes Care 2002;25(1):107-12
   PubMed Web of Science ®Google Scholar
• Shibasaki T, Hotta M, Masuda A, Plasma GH responses to GHRH and insulin-induced hypoglycaemia in man. J Clin Endocrinol Metab 1985;60(6):1265-7
   PubMed Web of Science ®Google Scholar
• Masuda A, Shibasaki T, Hotta M, Insulin-induced hypoglycaemia, L-dopa and arginine stimulate GH secretion through different mechanisms in man. Regul Pept 1990;31(1):53-64
   PubMed Web of Science ®Google Scholar
• Bokvist K, Olsen HL, Høy M, Characterisation of sulphonylurea and ATP-regulated K+ channels in rat pancreatic A-cells. Pflugers Arch 1999;438(4):428-36
   PubMed Web of Science ®Google Scholar
• United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 1998;128(3):165-75
   PubMed Web of Science ®Google Scholar
• Martin S, Kolb H, Beuth J, Change in patients' body weight after 12 months of treatment with glimepiride or glibenclamide in Type 2 diabetes: a multicentre retrospective cohort study. Diabetologia 2003;46(12):1611-17
   PubMed Web of Science ®Google Scholar
• Johnston PS, Lebovitz HE, Coniff RF, Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients. J Clin Endocrinol Metab 1998;83(5):1515-22
   PubMed Web of Science ®Google Scholar
• Schernthaner G, Grimaldi A, Di Mario U, GUIDE study: double-blind comparison of once-daily Gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 2004;34(8):535-42
   PubMed Web of Science ®Google Scholar
• de Boer H, Jansen M, Koerts J, Prevention of weight gain in type 2 diabetes requiring insulin treatment. Diabetes Obes Metab 2004;6(2):114-19
   PubMed Web of Science ®Google Scholar
• de Boer H, Keizers R, Jansen M, Glycaemic control without weight gain in insulin requiring type 2 diabetes: 1-year results of the GAME regimen. Diabetes Obes Metab 2006;8(5):517-23
   PubMed Web of Science ®Google Scholar
• Robb GH, Lowe SM. Lack of weight gain with gliclazide treatment for 30 months in type II diabetes. Curr Med Res Opin 1984;9(1):7-9
   PubMed Web of Science ®Google Scholar
• Campbell IW, Menzies DG, Chalmers J, One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabetes Metab 1994;20(4):394-400
   Web of Science ®Google Scholar
• Hermann LS, Schersten B, Bitzen PO, Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care 1994;17(10):1100-9
   PubMed Web of Science ®Google Scholar
• Marbury T, Huang WC, Strange P, Repaglinide versus glyburide: a one-year comparison trial. Diabetes Res Clin Pract 1999;43(3):155-66
   PubMed Web of Science ®Google Scholar
• Jain R, Osei K, Kupfer S, Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus. Pharmacotherapy 2006;26(10):1388-95
   PubMed Web of Science ®Google Scholar
• Lewitt MS, Yu VK, Rennie GC, Effects of combined insulin-sulfonylurea therapy in type II patients. Diabetes Care 1989;12(6):379-83
   PubMed Web of Science ®Google Scholar
• United Kingdom Prospective Diabetes Study (UKPDS). 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995;310(6972):83-8
   PubMed Web of Science ®Google Scholar
• Moses AM, Numann P, Miller M. Mechanism of chlorpropamide-induced antidiuretics in man. Evidence for release of ADH and enhancement of peripheral action. Metabolism 1973;22:59-66
   PubMed Web of Science ®Google Scholar
• Zini S, Ben-Ari Y, Ashford ML. Characterization of sulfonylurea receptors and the action of potassium channel openers on cholinergic neurotransmission in guinea pig isolated small intestine. J Pharmacol Exp Ther 1991;259(2):566-73
   PubMed Web of Science ®Google Scholar
• Adeniyi AF, Adeleye JO, Adeniyi CY. Diabetes, sexual dysfunction and therapeutic exercise: a 20 year review. Curr Diabetes Rev 2010;6(4):201-6
   PubMedGoogle Scholar
• Esposito K, Maiorino MI, Bellastella G, Determinants of female sexual dysfunction in type 2 diabetes. Int J Impot Res 2010;22(3):179-84
   PubMed Web of Science ®Google Scholar